Department of Clinical Pharmacology, Division of Pathological Science, Kyoto Pharmaceutical University, Kyoto, Japan.
Clin Exp Pharmacol Physiol. 2022 Dec;49(12):1342-1351. doi: 10.1111/1440-1681.13719. Epub 2022 Sep 18.
Autophagy is a self-degradation process of cytoplasmic components and occurs in the failing heart. Angiotensin II plays a critical role in the progression of heart failure and induces autophagy. We investigated the mechanism underlying angiotensin II-enhanced autophagy and examined the role of autophagy in angiotensin II-induced cardiomyocyte injury. Neonatal rat cardiomyocytes were treated with angiotensin II (1-100 nmol/L). Angiotensin II dose-dependently increased autophagy indicators of microtubule-associated protein 1 light chain (LC) 3-II and monodansylcadaverine-labelled vesicles. It also enhanced the intracellular production of reactive oxygen species (ROS), assessed by H2DCFDA, an intracellular ROS indicator. NADPH oxidase- and mitochondria-derived ROS production was increased by angiotensin II, while angiotensin II-induced LC3-II expression was suppressed by inhibitors of these sources of ROS. Confocal microscopy revealed that superoxide-producing mitochondria colocalized with lysosomes after the angiotensin II stimulation. Myocyte apoptosis was assessed by nuclear staining with DAPI and caspase-3 activity. A 6-h stimulation with angiotensin II did not affect myocyte apoptosis, while a co-treatment with 3-methyl-adenine (3MA), an autophagy inhibitor, augmented apoptosis. These results indicate that autophagy suppressed apoptosis because it removed damaged mitochondria in the early stages of the angiotensin II stimulation. A longer angiotensin II stimulation for 24 h induced apoptosis and propidium iodide-positive lethal myocytes, while the co-treatment with 3MA did not lead to further increases. In conclusion, angiotensin II-induced autophagy removes ROS-producing mitochondria. Autophagy is a beneficial phenomenon against myocyte apoptosis in the early phase, but its benefit was limited in the late phase of angiotensin II stimulation.
自噬是细胞质成分的自我降解过程,发生在衰竭的心脏中。血管紧张素 II 在心力衰竭的进展中起着关键作用,并诱导自噬。我们研究了血管紧张素 II 增强自噬的机制,并研究了自噬在血管紧张素 II 诱导的心肌细胞损伤中的作用。用血管紧张素 II(1-100nmol/L)处理新生大鼠心肌细胞。血管紧张素 II 呈剂量依赖性增加微管相关蛋白 1 轻链(LC)3-II 和单丹磺酰尸胺标记囊泡的自噬标志物。它还增强了细胞内活性氧(ROS)的产生,通过细胞内 ROS 指示剂 H2DCFDA 进行评估。血管紧张素 II 增加 NADPH 氧化酶和线粒体来源的 ROS 产生,而血管紧张素 II 诱导的 LC3-II 表达被这些 ROS 来源的抑制剂抑制。共聚焦显微镜显示,血管紧张素 II 刺激后,产生超氧化物的线粒体与溶酶体共定位。通过 DAPI 核染色和 caspase-3 活性评估心肌细胞凋亡。6 小时的血管紧张素 II 刺激不会影响心肌细胞凋亡,而自噬抑制剂 3-甲基腺嘌呤(3MA)的共同处理则增强了凋亡。这些结果表明,自噬抑制凋亡,因为它在血管紧张素 II 刺激的早期清除受损的线粒体。血管紧张素 II 刺激 24 小时诱导凋亡和碘化丙啶阳性致死性心肌细胞,而 3MA 的共同处理不会导致进一步增加。总之,血管紧张素 II 诱导的自噬去除产生 ROS 的线粒体。自噬在血管紧张素 II 刺激的早期阶段是一种有益的现象,可以对抗心肌细胞凋亡,但在晚期阶段的益处有限。